Interstitial Lung Disease Pipeline Insight
DelveInsight’s, “Interstitial Lung Diseases - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interstitial Lung Disease Understanding
Interstitial Lung Disease: Overview
Interstitial lung disease is a long-term (chronic) lung disease. It happens because of damage between the air sacs in the lung. The damage scars the lung and causes breathing problems. People with interstitial lung disease get breathless during exercise and may have a dry cough. These problems may get worse slowly or very quickly. The cause of interstitial lung disease is not known; however, a major contributing factor is thought to be inhaling environmental or occupational pollutants such as inorganic or organic dusts. People with interstitial lung disease usually go to the doctor because of shortness of breath or a cough. The doctor will probably use imaging tests of your lungs to find out the problem. Such tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy.
"Interstitial Lung Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Lung Disease pipeline landscape is provided which includes the disease overview and Interstitial Lung Disease treatment guidelines. The assessment part of the report embraces, in depth Interstitial Lung Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Lung Disease R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.
Interstitial Lung Disease Emerging Drugs Chapters
This segment of the Interstitial Lung Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interstitial Lung Disease Emerging Drugs
AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. At the back end of AD-214 is the Fc Fragment or tail region of a traditional monoclonal antibody that will extend the half-life or duration of time in which the i-body will stay in the body. Currently it is in phase 1 stage of development for the treatment of interstitial lung disease.
Abatacept: Bristol-Myers Squibb
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Currently, it is in phase 2 stage of development for the treatment of interstitial lung disease.
ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung
Further product details are provided in the report……..
Interstitial Lung Disease: Therapeutic Assessment
This segment of the report provides insights about the different Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Interstitial Lung Disease
There are approx. 100+ key companies which are developing the therapies for Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e. phase II include, Bristol-Myers Squibb.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Interstitial Lung Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Lung Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Lung Disease drugs.
Interstitial Lung Disease Report Insights
- Interstitial Lung Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Interstitial Lung Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Interstitial Lung Disease drugs?
- How many Interstitial Lung Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Lung Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Lung Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interstitial Lung Disease and their status?
- What are the key designations that have been granted to the emerging drugs?